Post treatment NLR is a predictor of response to immune checkpoint inhibitor therapy in patients with esophageal squamous cell carcinoma.

Cancer Cell Int · 2021 · PMC8262036 · PMID 34233686

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

The median of NLR in tumor-free people was 1.66, while the median of NLR at baseline in ESCC patients was 3.23, suggesting an increasing trend of NLR in patients with ESCC when compared with tumor-free people.

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.